Charles Rhyee
Stock Analyst at TD Cowen
(1.85)
# 3,078
Out of 5,180 analysts
78
Total ratings
34.78%
Success rate
-9.71%
Average return
Main Sectors:
Stocks Rated by Charles Rhyee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Upgrades: Buy | $15 | $9.42 | +59.24% | 5 | Mar 9, 2026 | |
| IQV IQVIA Holdings | Upgrades: Buy | $174 → $213 | $170.54 | +24.90% | 4 | Mar 9, 2026 | |
| VEEV Veeva Systems | Maintains: Buy | $380 → $300 | $175.66 | +70.78% | 5 | Mar 5, 2026 | |
| TDOC Teladoc Health | Maintains: Hold | $8 → $6 | $5.45 | +10.09% | 7 | Feb 26, 2026 | |
| CRL Charles River Laboratories International | Maintains: Buy | $251 → $235 | $172.50 | +36.23% | 7 | Feb 20, 2026 | |
| TALK Talkspace | Maintains: Buy | $6 → $9 | $5.18 | +73.91% | 3 | Feb 20, 2026 | |
| ICLR ICON Public Limited Company | Upgrades: Buy | $183 → $120 | $110.66 | +8.44% | 7 | Feb 18, 2026 | |
| MEDP Medpace Holdings | Upgrades: Hold | $462 → $419 | $480.19 | -12.74% | 7 | Feb 18, 2026 | |
| CI The Cigna Group | Maintains: Buy | $333 → $338 | $266.75 | +26.71% | 2 | Feb 9, 2026 | |
| MCK McKesson | Maintains: Buy | $1,000 → $1,012 | $865.36 | +16.95% | 5 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $44.50 | +3.37% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $1.96 | +206.12% | 8 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $400 | $314.14 | +27.33% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $99 → $100 | $71.82 | +39.24% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $183 → $225 | $211.31 | +6.48% | 3 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $27 | $26.92 | +0.30% | 2 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $100 → $50 | $5.26 | +850.57% | 3 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $56 | $5.14 | +989.49% | 2 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $360 → $280 | $8.02 | +3,391.27% | 3 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $50 | $2.28 | +2,092.98% | 2 | Jun 21, 2022 |
Fortrea Holdings
Mar 9, 2026
Upgrades: Buy
Price Target: $15
Current: $9.42
Upside: +59.24%
IQVIA Holdings
Mar 9, 2026
Upgrades: Buy
Price Target: $174 → $213
Current: $170.54
Upside: +24.90%
Veeva Systems
Mar 5, 2026
Maintains: Buy
Price Target: $380 → $300
Current: $175.66
Upside: +70.78%
Teladoc Health
Feb 26, 2026
Maintains: Hold
Price Target: $8 → $6
Current: $5.45
Upside: +10.09%
Charles River Laboratories International
Feb 20, 2026
Maintains: Buy
Price Target: $251 → $235
Current: $172.50
Upside: +36.23%
Talkspace
Feb 20, 2026
Maintains: Buy
Price Target: $6 → $9
Current: $5.18
Upside: +73.91%
ICON Public Limited Company
Feb 18, 2026
Upgrades: Buy
Price Target: $183 → $120
Current: $110.66
Upside: +8.44%
Medpace Holdings
Feb 18, 2026
Upgrades: Hold
Price Target: $462 → $419
Current: $480.19
Upside: -12.74%
The Cigna Group
Feb 9, 2026
Maintains: Buy
Price Target: $333 → $338
Current: $266.75
Upside: +26.71%
McKesson
Feb 5, 2026
Maintains: Buy
Price Target: $1,000 → $1,012
Current: $865.36
Upside: +16.95%
Jan 12, 2026
Initiates: Buy
Price Target: $46
Current: $44.50
Upside: +3.37%
Nov 10, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $1.96
Upside: +206.12%
Nov 10, 2025
Maintains: Buy
Price Target: $350 → $400
Current: $314.14
Upside: +27.33%
Nov 3, 2025
Maintains: Buy
Price Target: $99 → $100
Current: $71.82
Upside: +39.24%
Nov 3, 2025
Maintains: Buy
Price Target: $183 → $225
Current: $211.31
Upside: +6.48%
Nov 3, 2025
Maintains: Hold
Price Target: $30 → $27
Current: $26.92
Upside: +0.30%
Mar 23, 2023
Downgrades: Market Perform
Price Target: $100 → $50
Current: $5.26
Upside: +850.57%
Oct 20, 2022
Maintains: Outperform
Price Target: $70 → $56
Current: $5.14
Upside: +989.49%
Aug 16, 2022
Maintains: Outperform
Price Target: $360 → $280
Current: $8.02
Upside: +3,391.27%
Jun 21, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $2.28
Upside: +2,092.98%